Advanced Filters
noise

Brighton, Australia Clinical Trials

A listing of Brighton, Australia clinical trials actively recruiting patients volunteers.

Found 822 clinical trials
D Doherty Clinical Trials

Clinical Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of SOF-SKN in Healthy Participants

The goal of this study is to investigate the safety and tolerability of the topical application of SOF-SKN in healthy volunteers. The study will be divided into part 1 and part 2. Part 1, is a single ascending dose (SAD) design, while Part 2 is a multiple ascending dose (MAD) …

18 - 64 years of age All Phase 0
J Jessica Parish

A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults

This is a 2-Stage, Phase I/II Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis mRNA Vaccines (GBP560) in Healthy Adults (Aged 18 Years and Older)

18 years of age All Phase 1/2
P Philip Choi

Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke

STARS is a prospective, multicentre, open-label, dose escalation, Phase IIa study to assess the safety and tolerability of TBO-309, an adjuvant antiplatelet therapy, in patients with AIS. Acute ischaemic stroke (AIS) is caused by a severe blockage of an artery leading to immediate reduced blood flow to part of the …

18 years of age All Phase 2
A Andrea Tazbirkova, Dr

Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309

This is a Phase 1a/1b, first-in-human (FIH), open label study to evaluate the safety, tolerability, and pharmacokinetics (PK) of PMC-309, a mAb against the human VISTA ligand, in participants with advanced or metastatic solid tumors administered as a monotherapy and in combination with pembrolizumab.

18 years of age All Phase 1
A Ashleigh Poh

A Study of AP601 in Patients With Locally Unresectable Advanced or Metastatic Solid Tumors

A Phase 1, Open-Label Study of the Safety, Tolerability,Pharmacokinetics, Pharmacodynamics and Clinical Activity of AP601 in Patients with Solid Tumours.The study is designed to find the highest dose of AP601 that can be given safely. Participants will be assigned to one of six cohorts. Each cohort will receive a different …

18 years of age All Phase 1
N Nucleus Network, Melbourne

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PN-881 in Healthy Subjects.

The goal of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PN-881 in healthy adult participants.

18 - 65 years of age All Phase 1

Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)

The main objectives of this trial are to determine the recommended dose for expansion of xaluritamig (dose confirmation part only) and to determine the safety and tolerability of xaluritamig in adult, adolescent and pediatric participants with relapsed or refractory EWS.

2 years of age All Phase 1
N Nucleus Network, Melbourne

A Study to Evaluate Single and Multiple Doses of SEP-479 in Healthy Adult Participants

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and food effects of oral SEP-479 in healthy adult participants.

21 - 60 years of age All Phase 1

A Study of MK-7240 in Healthy Participants (MK-7240-009)

The goal of this study is to learn what happens to MK-7240 in a healthy person's body over time (pharmacokinetic or PK study). Researchers also want to learn about the safety of MK-7240 and if people tolerate it.

18 - 55 years of age All Phase 1
D Dr Charlotte Lemech

Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors

This clinical trial is designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of MT-304 in adults with advanced HER2-expressing solid tumors. The main questions it aims to answer are: What is the safety profile of MT-304 when administered alone or with nivolumab? What is the recommended Phase 2 …

18 years of age All Phase 1

Simplify language using AI